Characteristics of Lynch syndrome associated ovarian cancerWoolderink, J. M., De Bock, G. H., de Hullu, J. A., Hollema, H., Zweemer, R. P., Slangen, B. F. M., Gaarenstroom, K. N., van Beurden, M., van Doom, H. C., Sijmons, R. H., Vasen, H. F. A. & Mourits, M. J. E., Aug-2018, In : Gynecologic Oncology. 150, 2, p. 324-330 7 p.
Research output: Contribution to journal › Article › Academic › peer-review
Objective. To describe clinical characteristics of Lynch syndrome associated ovarian cancer and the efficacy of surveillance in the early detection of these ovarian cancers.
Methods. All Lynch syndrome associated ovarian cancer cases identified in either the Dutch Lynch syndrome registry (DLSR) between 1987 and 2016, and/or the cohort at the University Medical Center Groningen (UMCG) between 1993 and 2016 were included. Clinical data on age at diagnosis, mutation type, histological type, FIGO stage, treatment, follow-up and gynecological surveillance were collected.
Results. A total of 46/798 (6%) women in the DLSR and 7/80 (9%) in the UMCG cohort were identified as LS associated ovarian cancer patients. The median age at ovarian cancer diagnosis was 46.0 years (range 20-75 years). The most frequently reported histological type was endometrioid adenocarcinoma (40%; n = 21) and serous carcinoma (36%; n = 19). Most tumors (87%; n = 46) were detected at an early stage (FIGO I/II). Forty-one of 53 (77%) patients were diagnosed with ovarian cancer before LS was diagnosed. In the other 12/53 (23%) women, ovarian cancer developed after starting annual gynecological surveillance for LS; three ovarian cancers were screen-detected in asymptomatic women. Overall survival was 83%.
Conclusion. Ovarian cancer in women with LS has a wide age-range of onset, is usually diagnosed at an early stage with predominantly endometrioid type histology and a good overall survival. The early stage at diagnosis could not be attributed to annual gynecological surveillance. (C) 2018 Published by Elsevier Inc.
|Number of pages||7|
|Publication status||Published - Aug-2018|
- Lynch syndrome, Ovarian cancer, Surveillance, Survival, NONPOLYPOSIS COLORECTAL-CANCER, RANDOMIZED CONTROLLED-TRIAL, BRCA1/2 MUTATION CARRIERS, ENDOMETRIAL CANCER, GYNECOLOGIC CANCERS, CLINICAL-FEATURES, MSH2 MUTATION, EARLY-ONSET, RISK, GERMLINE